Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

The Accu-Chek SmartGuide CGM solution provides real-time glucose readings for type 1 and type 2 diabetes patients on flexible insulin therapy. Its AI-trained algorithms predict glucose levels 30 minutes in advance, forecast their development within two hours, and estimate nocturnal hypoglycemia risk. The solution aims to empower users to proactively manage their glucose levels and prevent complications. The sensor's high accuracy has been demonstrated in clinical evaluations. It seamlessly integrates with the Accu-Chek Care platform, allowing healthcare professionals to access comprehensive data and make informed decisions. The solution will be available in selected European markets in the coming months. Roche, the developer of the solution, is committed to improving access to healthcare and partnering with stakeholders to deliver personalized care. The solution is designed to alleviate concerns about nighttime hypoglycemia and empower individuals to take control of their condition.